Background
Methods
Study populations
HPV testing
Statistical analyses
Results
Input DNA (5 ng/μl) | 13HR HPV Types (FAM) | Internal Control (JOE) | HPV Status | |||
---|---|---|---|---|---|---|
Sample | Total Volume (μl) | Volume (μl) | Input DNA (ng) | Ct | Ct | |
HPV positive controls | ||||||
CaSki (HPV16) | 20 | 2 | 10 | 15.74 | 27.26 | + |
10 | 1 | 5 | 16.15 | 28.61 | + | |
HeLa (HPV18) | 20 | 2 | 10 | 22.26 | 26.23 | + |
10 | 1 | 5 | 23.03 | 26.26 | + | |
MS751 (HPV45) | 20 | 2 | 10 | 26.90 | 29.79 | + |
10 | 1 | 5 | 27.96 | 29.91 | + | |
ME180 (HPV39/18) | 20 | 2 | 10 | 27.61 | 25.99 | + |
10 | 1 | 5 | 27.72 | 25.96 | + | |
Unknown samples from cell lysate | ||||||
S1 DD015959 | 20 | 2 | NDa | 24.05 | – | |
10 | 1 | ND | 24.80 | – | ||
S2 DD015960 | 20 | 2 | 17.60 | 27.59 | + | |
10 | 1 | 18.02 | 28.10 | + | ||
S3 DD015963 | 20 | 2 | 16.85 | 20.78 | + | |
10 | 1 | 17.20 | 21.30 | + | ||
S6 DD015964 | 20 | 2 | 16.01 | 22.05 | + | |
10 | 1 | 16.80 | 22.70 | + | ||
HPV negative control (C33A) | 20 | 2 | 10 | ND | 25.66 | – |
10 | 1 | 5 | ND | 25.04 | – | |
Controls from kit | ||||||
Positive control (Kit) | 20 | 2 | 23.88 | 23.39 | + | |
10 | 1 | 25.07 | 25.68 | + | ||
Negative control (Kit)a | 20 | 2 | ND | ND | – | |
10 | 1 | ND | ND | – |
Age group | HPV-No. | HPV+ No. | HPV+ (%) (95% CI) | OR | 95% CI of OR | P value |
---|---|---|---|---|---|---|
< 30 | 136 | 36 | 21 (16-28) | Ref | ||
30-39 | 474 | 47 | 9 (7-12) | 0.43 | 0.27 to 0.69 | 0.0004 |
40-49 | 401 | 30 | 7 (5- 10) | 0.33 | 0.20 to 0.56 | < 0.0001 |
50-59 | 244 | 18 | 7 (4-11) | 0.33 | 0.18 to 0.60 | 0.0003 |
≥60 | 43 | 7 | 14 (7-26) | ns |
HPV type | No. | Percentage in 13HR (%) | |
---|---|---|---|
13 HR types | 16 | 32 | 22% |
18 | 16 | 11% | |
31 | 4 | 3% | |
33 | 2 | 1% | |
35 | 6 | 4% | |
39 | 16 | 11% | |
45 | 12 | 8% | |
51 | 5 | 3% | |
52 | 12 | 8% | |
56 | 6 | 4% | |
58 | 15 | 10% | |
59 | 10 | 7% | |
68 | 7 | 5% | |
Total | 143 |